GD
Guyer David R
Director
BoardM
Insider track record
Board DirectorNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the full record of transactions filed by Guyer David R, Director. Officer active across 2 companies, notably EyePoint Pharmaceuticals, Inc.. Cumulatively, 19 disclosures have been recorded. Breakdown: 0 buy · 11 sells. History available since 9 February 2022. The latest transaction was filed on 12 July 2024 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Guyer David R
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
3,250 shares@ US$3.5021.1% of flowCommon StockSEC:0001562180-24-005752:0
6,525 shares@ US$3.2639.3% of flowCommon StockSEC:0001562180-24-004638:0
6,525 shares@ US$3.2639.6% of flowCommon StockSEC:0001562180-24-004106:0
3,000 shares0Common StockSEC:0001562180-23-001338:0
2,500 shares0Common StockSEC:0001562180-22-001419:0
18,598 sharesCommon StockSEC:0001104659-16-092984:0
14,198 sharesCommon StockSEC:0001104659-16-092984:1
3,200 sharesCommon StockSEC:0001104659-16-092984:2
600 sharesCommon StockSEC:0001104659-16-092984:3
600 sharesCommon StockSEC:0001104659-16-092984:4
5,750 sharesCommon StockSEC:0001104659-16-088114:0
862 sharesCommon StockSEC:0001104659-16-088114:1
600 sharesCommon StockSEC:0001104659-16-088114:2
1,121 sharesCommon StockSEC:0001104659-16-088114:3
578 sharesCommon StockSEC:0001104659-16-088114:4
108 sharesCommon StockSEC:0001104659-16-088114:5
18,582 sharesCommon StockSEC:0001104659-16-087785:0
11,631 sharesCommon StockSEC:0001104659-16-087785:1
6,951 sharesCommon StockSEC:0001104659-16-087785:2
About Guyer David R
David R. Guyer is a Director at EyePoint Pharmaceuticals, Inc. As a board member, he participates in overseeing the company's activities and making strategic decisions. David brings his expertise and experience to guide EyePoint in its growth and innovation initiatives. His role is essential in ensuring the company's good governance and regulatory compliance.